Hemiparkinsonism is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Hemiparkinsonism is a rare neurological syndrome characterized by Parkinsonian features affecting only one side of the body (unilateral). It represents a distinct clinical entity within the spectrum of Parkinsonian disorders, typically resulting from localized damage to the substantia nigra pars compacta on one side of the brain [1].
Unlike classic Parkinson's disease, which typically presents with bilateral symptoms, hemiparkinsonism demonstrates a lateralized pattern of motor impairment, providing important clues about its underlying etiology.
¶ Etiology and Causes
-
Stroke (Cerebrovascular Hemiparkinsonism)
- Lacunar infarcts in the substantia nigra
- Small vessel disease affecting unilateral dopaminergic pathways
- Ischemic damage to the nigrostriatal pathway
-
Brain Tumors
- Tumors compressing the substantia nigra
- Metastatic lesions affecting unilateral dopaminergic neurons
- Primary brain tumors in the midbrain region
-
Traumatic Brain Injury
- Unilateral head trauma damaging the substantia nigra
- Penetrating injuries to the midbrain
-
Neurodegeneration
- Unilateral progression of Parkinson's disease
- Rare cases of truly unilateral Parkinsonian degeneration
-
Other Causes
- Infection (encephalitis affecting one side)
- Vascular malformations
- Surgical complications
- History of stroke or transient ischemic attacks
- Hypertension
- Diabetes mellitus
- History of head trauma
- Occupational exposures
The characteristic unilateral symptoms result from:
- Selective loss of dopaminergic neurons in the substantia nigra pars compacta on one side
- Disruption of the nigrostriatal pathway (dopaminergic projections to the striatum)
- Preservation of the contralateral nigrostriatal system
- Decreased dopamine in the ipsilateral striatum
- Loss of neuromelanin-containing neurons
- Reduced tyrosine hydroxylase activity
- Compensatory mechanisms in the unaffected hemisphere
-
Resting Tremor
- Pill-rolling tremor of the fingers
- Present at rest, often improves with movement
- Typically begins in the hand
-
Bradykinesia
- Decreased spontaneous movement
- Slowed finger-tap movements
- Reduced arm swing on the affected side
-
Muscle Rigidity
- Cogwheel rigidity
- Increased tone in affected limbs
- Resistance to passive movement
-
Postural Instability
- May be less prominent than in idiopathic Parkinson's disease
- Usually develops later in the disease course
- Sleep disorders: REM sleep behavior disorder may occur
- Mood changes: Depression and anxiety
- Cognitive changes: Mild cognitive impairment in some cases
- Autonomic dysfunction: Less prominent than in classic PD
- Symptoms remain lateralized in many cases
- May spread to contralateral side over time (5-10 years)
- Rate of progression varies significantly
- Presence of at least two cardinal features:
- Resting tremor
- Bradykinesia
- Rigidity
- Unilateral onset and predominance
- Asymmetric DAT scan findings
- Exclusion of other causes
- Neurological examination: Detailed assessment of lateralized symptoms
- DaTscan (FP-CIT SPECT): Shows reduced dopamine transporter binding on the affected side
- MRI brain: Rules out structural causes (stroke, tumor)
- Transcranial sonography: May show increased echogenicity of substantia nigra
- Classic Parkinson's disease (will become bilateral)
- Progressive supranuclear palsy
- Corticobasal degeneration
- Multiple system atrophy
- Vascular parkinsonism
-
Dopamine Precursors
- Levodopa/Carbidopa: Effective but may cause dyskinesias
- Response typically good but may be less dramatic than in classic PD
-
Dopamine Agonists
- Pramipexole, ropinirole
- May be used as first-line or adjunct therapy
-
MAO-B Inhibitors
- Selegiline, rasagiline
- Mild symptomatic benefit
-
Anticholinergics
- Trihexyphenidyl
- May help tremor-dominant cases
- Deep Brain Stimulation (DBS): Particularly effective for tremor
- Target: Vim nucleus of thalamus or STN
- Requires careful patient selection
- Physical therapy: Maintains mobility and balance
- Occupational therapy: Adaptive strategies
- Speech therapy: If dysarthria develops
- Generally slower progression than classic Parkinson's disease
- Many patients maintain good function for years
- Eventual bilateral involvement in 30-50% of cases
- Good response to dopaminergic therapy in most cases
- Quality of life often preserved for extended periods
- Risk of falls increases with disease progression
- Rare condition representing <5% of all Parkinsonian syndromes
- More common in older adults
- Vascular etiology increasingly recognized
- Advanced MRI techniques to characterize structural changes
- PET studies of dopamine metabolism
- Functional connectivity mapping
- Development of biomarkers to predict progression
- Genetic risk factors for unilateral susceptibility
The study of Hemiparkinsonism has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Jellinger KA. Vascular parkinsonism: clinicopathological study. J Neurol. 1999;246(11):1017-1026. DOI:10.1007/s004150050510
-
FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4(3):249-260. DOI:10.1002/mds.870040308
-
Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630-640. DOI:10.1002/mds.20088
-
Rampello L, Alvano A, Raffaele R, Vecchio I, Malaguarnera M. Stroke-induced parkinsonism: a case report and review of the literature. Arch Gerontol Geriatr. 2007;45(2):169-171. DOI:10.1016/j.archger.2006.10.009
-
Yamanouchi H, Nagura H. Unilateral parkinsonism and hemiatrophy: a clinicopathological study. J Neurol Sci. 1997;151(2):175-179. DOI:10.1016/S0022-510X(9700114-9
-
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. DOI:10.1016/S0140-6736(1461393-3
-
Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793. DOI:10.1016/S0140-6736(0416305-8
-
Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264-1310. DOI:10.1002/mds.27115